Takeda Commits to Vaxs with Massive Dengue Study

Apr 07, 2017


Japan's Takeda Pharmaceutical has completed enrollment for a 20,000-subject phase 3 dengue vaccine trial, the largest clinical study in its history.

The global study will test the experimental vaccine on 20,100 children and adolescents in eight countries in Latin America and Asia where the mosquito-borne disease is endemic.

The vaccine could potentially rival Sanofi Pasteur's Dengvaxia, which did not prove to protect equally against the four different serotypes of dengue.

Takeda is pushing to become more global with its vaccines business under the leadership of CEO Christophe Weber. Last November, Takeda announced it planned to invest more than $107 million to build a new manufacturing plant in Germany for its dengue vaccine candidate.

 Read the CNBC article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments